Novartis Tafinlar + Mekinist Approved by FDA for Pediatric Patients with BRAF V600E Low-Grade Glioma, the Most Common Pediatric Brain Cancer

Novartis announced the US FDA granted approval for Tafinlar® + Mekinist® for the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.